Qualigen Therapeutics, Inc. (AIXC)

Market Cap	4.80M
Revenue (ttm)	n/a
Net Income (ttm)	-8.09M
Shares Out	1.70M
EPS (ttm)	-5.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	158,798
Open	3.260
Previous Close	n/a
Day's Range	2.750 - 3.270
52-Week Range	1.610 - 8.810
Beta	0.28
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 21, 2025

About AIXC

Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company’s lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was founded in 1996 and is based in Carlsbad, California.

• Founded: 1996
• Employees: 4
• Stock Exchange: NASDAQ
• Ticker Symbol: AIXC
• Website: https://qlgntx.com